Inhibition of Cyclooxygenase-2 Suppresses Lymph Node Metastasis via Reduction of Lymphangiogenesis

Caname Iwata,1,2 Mitsunobu R. Kano,1,3 Akiyoshi Komuro,1 Masako Oka,1 Kunihiko Kiyono,1 Erik Johansson,1 Yasuyuki Morishita,1 Masakazu Yashiro,1 Kosei Hirakawa,4 Michio Kaminishi,2 and Kohei Miyazono1,3

Abstract

Cyclooxygenase-2 (COX-2) inhibitor has been reported to suppress tumor progression. However, it is unclear whether this inhibitor can also prevent lymphatic metastasis. To determine the effects of COX-2 inhibitor on lymphatic metastasis, etodolac, a COX-2 inhibitor, was given p.o. to mice bearing orthotopic xenografts or with carcinomatous peritonitis induced with a highly metastatic human diffuse-type gastric carcinoma cell line, OCUM-2MLN. Tumor lymphangiogenesis was significantly decreased in etodolac-treated mice compared with control mice. Consistent with this decrease in lymphangiogenesis, the total weight of metastatic lymph nodes was less in etodolac-treated mice than in control mice. Immunohistochemical analysis revealed that the major source of vascular endothelial growth factor-C (VEGF-C) and VEGF-D was F4/80-positive macrophages in our models. The mRNA levels of VEGF-C in mouse macrophage-like RAW264.7 cells, as well as those in tumor tissues, were suppressed by etodolac. Supporting these findings, etodolac also inhibited lymphangiogenesis in a model of chronic aseptic peritonitis, suggesting that COX-2 can enhance lymphangiogenesis in the absence of cancer cells. Our findings suggest that COX-2 inhibitor may be useful for prophylaxis of lymph node metastasis by reducing macrophage-mediated tumor lymphangiogenesis. [Cancer Res 2007;67(21):10181–9]

Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

Requests for reprints: Kohei Miyazono, Department of Molecular Pathology, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan. Phone: 81-3-5841-3345; Fax: 81-3-5841-3354; E-mail: miyazono-ind@umin.ac.jp.

©2007 American Association for Cancer Research.

doi:10.1158/0008-5472.CAN-07-2366

Introduction

Lymph node metastasis is a common occurrence in cancer, and lymphatic vessels serve as an important route for the spread of cancer cells (1, 2). Lymphatic metastasis was previously believed to be a passive process in which detached cancer cells reach lymph nodes through preexisting local lymphatic vessels (3). However, recent studies have suggested that lymphangiogenesis actively contributes to metastasis based on the observations that lymphatic vessel density is correlated with the extent of lymph node metastasis and/or unfavorable prognosis of certain cancers (2, 4, 5). Moreover, some animal tumor models have revealed that expression of lymphangiogenic growth factors leads to formation of lymphatic vessels and that lymphangiogenesis is accompanied by enhanced lymphatic metastasis (2). These findings strongly suggest that lymphatic metastasis can be blocked by inhibition of tumor lymphangiogenesis (1, 6, 7).

The best studied lymphangiogenic signaling system is the vascular endothelial growth factor-C (VEGF-C)/VEGF-D and VEGF receptor 3 (VEGF-R3) signaling axis, which has been shown to play a central role in lymphangiogenesis in animal models (1, 2, 4). Elevated expression of VEGF-C or VEGF-D has been observed in many human cancers (2, 4). A number of studies have shown that levels of expression of VEGF-C in primary tumor correlate with lymphatic vessel invasion and/or lymph node metastasis (2, 4, 8), although the correlation between VEGF-D and metastasis is currently unclear (4, 9). These ligands are thought to be secreted from tumor cells; in addition, macrophages in the peritumoral stroma (i.e., tumor-associated macrophages) have also been reported to produce VEGF-C and VEGF-D in certain cancers and to induce lymphangiogenesis (10). The contribution of inflammatory cells to lymphangiogenesis has also been shown in mouse models of inflammation (11, 12).

Epidemiologic studies have shown that regular intake of nonsteroidal antiinflammatory drugs (NSAID), prototypic inhibitors of cyclooxygenase (COX), such as aspirin, can reduce the risk of development of some cancers (13). In addition, overexpression of COX-2, which is induced by both inflammatory and mitogenic stimuli, is commonly found in many cancers (14-16), suggesting that COX-2 contributes to the process of carcinogenesis. Direct molecular evidence that COX-2 contributes to carcinogenesis has been obtained from studies in animals engineered to be deficient in expression of the COX-2 gene (17) or treated with COX-2 selective inhibitors (18). Thus far, several mechanisms by which COX-2 contributes to progression of cancer have been reported, including stimulation of proliferation and inhibition of apoptosis of cancer cells, stimulation of cancer cell invasion and angiogenesis, and suppression of immune responses (14, 19).

The major role of COX-2 in angiogenesis is thought to be induction of the synthesis of prostanoids, which then stimulate the secretion of proangiogenic factors, including VEGF-A and fibroblast growth factor-2, from cancer cells and/or stromal fibroblasts (20, 21). In addition, COX-2 stimulates the proliferation (22), migration, and tube formation of vascular endothelial cells (20). Several clinical studies have indeed shown a correlation between level of COX-2 expression and extent of angiogenesis in cancer (23).

In contrast to the effect of COX-2 on angiogenesis, that on lymphangiogenesis remains poorly understood, although correlations between COX-2 expression and lymphangiogenesis or lymph node metastasis have been reported for several human cancers.
(24–28). To examine whether COX-2 is involved in lymphatic metastasis, we evaluated the effects of treatment with a COX-2 selective inhibitor, etodolac (29, 30), on tumor lymphangiogenesis and extent of lymph node metastasis using a highly metastatic human diffuse-type gastric carcinoma cell line, OCUM-2MLN (31). We also examined the effects of etodolac on lymphangiogenesis in two other animal models, i.e., a model of carcinomatous peritonitis and one of chronic aseptic peritonitis. Our findings suggest that etodolac has antilymphangiogenic activity in vivo and that inhibition of COX-2 could suppress tumor lymphangiogenesis and lymph node metastasis.

### Materials and Methods

**Animals and cells.** Immunodeficient BALB/c nu/nu mice at 4 to 5 weeks of age, obtained from Charles River Laboratories, were used for the model of lymph node metastasis and a model of carcinomatous peritonitis. Specific pathogen-free BALB/c mice at 4 to 5 weeks of age, obtained from Sankyo Laboratory, were used for a model of chronic aseptic peritonitis. Mice were treated in accordance with the policies of the Animal Ethics Committee of the University of Tokyo. OCUM-2MLN, a human diffuse-type gastric carcinoma cell line with a high rate of metastasis to lymph nodes, was previously established (31). RAW264.7, a mouse macrophage cell line, was a kind gift from Dr. Tadashi Muroi (NIH Sciences). Human dermal lymphatic microvascular endothelial cells (HDLEC) were obtained from Cambrex.

**Model of lymph node metastasis.** We used a lentiviral vector (a kind gift from Dr. Hiroyuki Miyoshi, RIKEN; ref. 32) to express the green fluorescent protein (GFP) gene stably in OCUM-2MLN. A total of 5 × 10⁶ cells in 50 μL of PBS were subserosally inoculated into the gastric walls of BALB/c nu/nu mice as previously described (31) under deep inhalation anesthesia with ether. Four weeks after inoculation, the mice were sacrificed for evaluation. Etodolac (500 ppm in food; obtained from Nippon Shinyaku) or vehicle control was given p.o. throughout the experimental period from the inoculation of cancer cells until evaluation (n = 7 mice for each group). The experiment was repeated thrice.

Spread of cancer cells from the site of inoculation in the stomach was observed with a VB-G25 fluorescence stereomicroscope (Keyence). The captured fluorescence images and bright-field images were merged using Adobe Photoshop software (Adobe Systems). All GFP-positive, i.e., metastatic, lymph nodes were collected, and the total weight of these lymph nodes was measured. Stomachs were excised, fixed for 1 h in 10% neutral buffered formalin at room temperature, washed overnight in PBS containing 10% sucrose at 4°C, embedded in optimal cutting temperature compound (Tissue-Tek, Sakura Finetek), and snap frozen in dry-iced acetone for immunohistochemical examination.

To visualize the lymphatic vessels in normal gastric wall, we injected India ink into the gastric wall of anesthetized control mice and immediately observed the draining lymphatic vessels by stereomicroscope. **Model of carcinomatous peritonitis.** We i.p. injected OCUM-2MLN cells (5 × 10⁶) into BALB/c nu/nu mice to induce carcinomatous peritonitis. The mice were sacrificed 2 weeks after inoculation and were evaluated. Etodolac (500 ppm in food) or vehicle control was given p.o. during the same period (n = 5 for each group). The mice were then sacrificed, and their diaphragms excised and prepared for H&E staining and immunostaining as described above. The experiment was repeated twice.

**Immunohistochemistry.** Whole mounts of diaphragms and 20-μm cryostat sections of postfixed frozen samples were stained with one or more primary antibodies. We used the following antibodies for immunostaining. For staining of lymphatic vessels, rabbit polyclonal antibody to LYVE-1 (1:200 dilution; Abcam), rat monoclonal antibody to mouse LYVE-1 (1:100 dilution; a kind gift from Drs. Yuichi Okie and Toshio Suda, Keio University), or rabbit polyclonal antibody to Proxl (1:200 dilution; Chemicon) was used. Rat monoclonal antibody to mouse platelet/endothelial cell adhesion molecule 1 (PECAM-1; 1:200 dilution; BD PharMingen) was used for staining of blood vessels. For staining of VEGF-C and VEGF-D, goat polyclonal antibody to VEGF-C (C-20; 1:50 dilution, Santa Cruz Technology), and rabbit polyclonal antibody to VEGF-D (H-144; 1:50 dilution, Santa Cruz Technology) were used, respectively. Macrophages were immunostained with rat monoclonal antibody to F4/80 (1:20 dilution; Serotec) or rat monoclonal antibody to mouse CD11b (1:200 dilution; Chemicon). Dividing cells were stained with rabbit polyclonal antibody to Ki-67 (1:1,000 dilution; Novo Castra). COX-2 was stained with affinity-purified rabbit polyclonal antibody to COX-2 (1:100 dilution; Cayman Chemical). Subsequently, specimens were incubated with corresponding secondary antibodies labeled with Alexa Fluoros 488, 594, or 647 (Invitrogen-Molecular Probes). In control experiments, the primary antibody was omitted. Specimens were examined with a LSM 510 META confocal microscope (Carl Zeiss) or a fluorescence stereomicroscope.

**Morphometric analysis.** In the model of lymph node metastasis, we double-stained tumor sections for LYVE-1 and PECAM-1 to examine lymphatic and blood vessel densities. For each tumor section, five hotspots (i.e., fields with the highest vascular density) in tumor areas were evaluated at magnification of 200×. Digital images of LYVE-1-positive lymphatic vessels and highly PECAM-1-positive blood vessels were captured. Area densities (percentage of total tissue area) of lymphatic vessels or blood vessels were then calculated using ImageJ software (NIH).

In the model of carcinomatous peritonitis, whole-mount diaphragms stained for LYVE-1 were evaluated from the pleural side. Lymphatic sprouts, defined as tapered projections, were counted at magnification of 100× in 10 microscopic fields per diaphragm. In the model of chronic aseptic peritonitis, whole-mount diaphragms stained for LYVE-1 and CD11b were evaluated from the peritoneal side. Inflammatory plaques, defined as accumulations of inflammatory cells, especially of macrophages, had formed on the peritoneal surface of the diaphragm. For each diaphragm, 10 microscopic fields in inflammatory plaques were evaluated at magnification of 200×. Digital images of LYVE-1–positive lymphatic vessels were captured, and the area density of lymphatic vessel was calculated using ImageJ software.

**RNA isolation and quantitative reverse transcription–PCR.** Gastric walls with or without tumor were excised from mice, immersed in RNAlater (Qiagen), embedded in optimal cutting temperature compound, and snap frozen. Total RNAs were extracted from tissue sections using the RNeasy micro kit (Qiagen). Total RNAs from RAW264.7 and HDLECs were extracted using the RNeasy mini kit (Qiagen). First-strand cDNAs were synthesized using the Quantitect reverse transcription kit (Qiagen) with random hexamer primers. Quantitative real-time reverse transcription–PCR (RT-PCR) analysis was done using the 7500 Fast Real-Time PCR system (Applied Biosystems). The primer sequences used are given in Supplementary Table S1.

**Cell growth assay.** Cell growth was determined with a WST-8 assay kit (Nacalai Tesque). Briefly, HDLECs (1 × 10⁶ cells per well) or OCUM-2MLN (7.5 × 10⁵ cells per well) in 96-well plates were incubated overnight. Thereafter, the medium was replaced with a new medium containing etodolac and/or lipopolysaccharide (LPS; 0.111 μg/ml Sigma-Aldrich). After 24 to 96 h of incubation, the WST-8 reagent was added to the culture. After
2 h of incubation, absorbance at 450 nm was measured with a microplate reader (Bio-Rad).

Statistical analysis. Statistical analysis was carried out using Excel software (Microsoft). Results were compared by Student’s t test and expressed as mean values with SE. Differences were considered statistically significant at \( P < 0.05 \). All statistical tests were two-sided. Effects of etodolac on the growth of OCUM-2MLN were evaluated by multivariate ANOVA testing using JMP software (SAS Institute).

Results

Spread of cancer cells via lymphatic vessels in a murine model of lymph node metastasis of gastric cancer. To determine lymph node metastasis \textit{in vivo}, we used an animal model of human metastatic gastric carcinoma, in which OCUM-2MLN cells expressing GFP were inoculated orthotopically into the gastric wall of BALB/c nu/nu mice. Examination by fluorescence stereomicroscope 4 weeks after inoculation revealed that the cancer cells had metastasized from the site of inoculation into the regional lymph nodes. Using this model, we examined tumor lymphangiogenesis and spread of cancer cells through the lymphatic vessels. The cancer cells in this model exhibited invasion into peritumoral lymphatic vessels and spread along lymphatic vessels in the gastric wall toward the regional lymph nodes (Fig. 1A). Visualization by intravital injection of India ink into the gastric wall of control mice (Supplementary Fig. S1) revealed that the sizes and numbers of the lymphatic vessels were dramatically increased in the mice inoculated with gastric cancer cells (Fig. 1A) compared with those in control mice. To confirm the increase in lymphatic vessels in the mice bearing cancer cells, we double-stained the sections of the gastric wall of the mice using LYVE-1, a specific lymphatic vessel marker, and Ki-67, a marker of cell proliferation. Some dividing lymphatic endothelial cells stained by both LYVE-1 and Ki-67 were observed in the gastric wall of the tumor-bearing mice (Fig. 1B), demonstrating induction of lymphangiogenesis in this model.

Suppression of lymphangiogenesis and lymph node metastasis by etodolac in the model of lymph node metastasis. We examined whether etodolac, a COX-2 inhibitor, inhibits

![Figure 1](https://example.com/figure1.png)

**Figure 1.** Effects of etodolac on a murine model of lymph node metastasis of gastric carcinoma. A, spread of GFP-expressing OCUM-2MLN cells 4 wk after inoculation into gastric wall of BALB/c nu/nu mouse. GFP-positive cancer cells (purple) which have invaded peritumoral lymphatic vessels in the gastric wall and metastasized to regional lymph nodes (arrowheads). Arrows, orthotopically inoculated OCUM-2MLN tumor. Scale bar, 1 mm. B, cross-section of gastric wall with GFP-positive cancer cells (blue), stained for lymphatic vessels (anti–LYVE-1; red) and dividing nuclei (anti–Ki-67; green). Arrowheads, lymphatic endothelial cells positive for Ki-67. Scale bar, 20 \( \mu \)m. C, orthotopic GFP-positive OCUM-2MLN (blue) tumor in control mice or in etodolac-treated mice, stained for lymphatic vessels (anti–LYVE-1; red) and blood vessels (anti–PECAM-1; green). Scale bar, 50 \( \mu \)m. D, left, quantification of tumor lymphatic vessels. Columns, mean area density of LYVE-1-positive pixels per microscopic field; bars, SE (data from one section per tumor, with 10 images per section).**, \( P = 0.008 \), two-sided Student’s t test. Middle, total weights of metastatic lymph nodes from control mice and etodolac-treated mice. Columns, mean; bars, with SE.**, \( P = 0.006 \). Right, quantification of tumor blood vessels. Columns, mean area density of pixels highly positive for PECAM-1 per microscopic field; bars, SE.**, \( P = 0.002 \).
lymphangiogenesis and lymph node metastasis in this model. Etodolac (500 ppm in food) or vehicle control was given p.o. throughout the experimental period, from inoculation of cancer cells to evaluation of lymphangiogenesis and lymph node metastasis. We stained the sections of tumors in the gastric wall for LYVE-1. As shown in Fig. 1C, tumor lymphangiogenesis was less prominent in the etodolac-treated mice than in the control mice. Quantification of LYVE-1–positive areas in hotspots confirmed these findings (Fig. 1D, left). We also determined the extent of lymph node metastasis by measuring the total weight of metastatic lymph nodes identified by expression of GFP using a fluorescence stereomicroscope (Supplementary Fig. S2). Consistent with the decrease in density of lymphatic vessels, the total weight of metastatic lymph nodes was significantly less in etodolac-treated mice than in the control mice (Fig. 1D, middle).

To determine whether etodolac affects angiogenesis, as well as lymphangiogenesis, we examined tumor angiogenesis by staining sections of tumors for PECAM-1. The relative area occupied by vessels strongly positive for PECAM-1 was significantly decreased in the etodolac-treated mice compared with the control mice (Fig. 1D, right).

**Lymphatic vessels in the diaphragm in normal mice and those with carcinomatous peritonitis.** To evaluate tumor lymphangiogenesis in another fashion, we established a new model of lymphangiogenesis, in which the lymphatic vessels of the diaphragm of mice can be observed. We first observed the physiologic function and morphologic characteristics of lymphatic vessels in the diaphragm. Only 20 min after the injection of India ink into the abdominal cavity, lymphatic vessels in the diaphragm were stained with the ink (Supplementary Fig. S3A). Lymphatic vessels in the diaphragm were also observed by whole-mount immunostaining for LYVE-1 and Prox1 as specific markers of lymphatic vessels (Supplementary Fig. S3B). Immunostaining of sections of the diaphragm for LYVE-1 revealed a lymphatic network consisting of lymphatic lacunae on the peritoneal side and intermuscular lymphatic vessels (Fig. 2A, left; ref. 33).

Next, we observed the diaphragms of mice with carcinomatous peritonitis. Two weeks after i.p. inoculation of OCUM-2MLN cells (5 × 10⁶) into BALB/c nu/nu mice, cancerous ascites had accumulated, and dissemination of cancer on the peritoneal surface of the diaphragm was observed (data not shown). Sections of diaphragm revealed that these sites of dissemination consisted of cancer cells and F4/80-positive macrophages (Fig. 2A, right). The lymphatic vessels in the diaphragm were increased in both size and number. Outgrowths of the lymphatic vessels into the site of dissemination were also detected (Fig. 2A).

**Suppression of lymphangiogenesis by etodolac in the model of carcinomatous peritonitis.** As described above, lymphatic vessels in the diaphragm in normal mice and those with carcinomatous peritonitis.
vessels in the diaphragm can be evaluated not only by using tissue sections but also by using whole-mount samples. Using this model, we examined the effects of etodolac on tumor lymphangiogenesis. Etodolac or vehicle control was continuously given for 2 weeks from the time of inoculation of cancer cells to evaluation of lymphangiogenesis. We observed the lymphatic vessels in the diaphragm by whole-mount immunostaining for LYVE-1 from the pleural side. More sprouts were detected along lymphatic vessels over the entire diaphragm in the cancer-inoculated mice than in the cancer-free mice (Fig. 2B). However, the number of sprouts was less in the etodolac-treated mice than in the untreated mice (Fig. 2B). Quantification of lymphatic sprouts revealed significant reduction of lymphangiogenesis by treatment with etodolac (Fig. 2C).

Expression of VEGF-C/VEGF-D and COX-2 in tumor tissues. Macrophages have been suggested to be the major cellular sources of lymphangiogenic growth factors VEGF-C and VEGF-D (10–12). To determine whether macrophages are also the major source of these ligands in our model, we did immunohistochemical staining for macrophage marker F4/80 and VEGF-C or VEGF-D. In this model, many cells positive for VEGF-C (Fig. 3A, a) and VEGF-D (Fig. 3A, b) were F4/80-positive macrophages. Although certain cancer cells have also been reported to secrete these ligands, OCUM-2MLN cells were negative for VEGF-C (Fig. 3A, a) and VEGF-D (Fig. 3A, b) staining. These observations indicate that macrophages are the major sources of lymphangiogenic growth factors in this model.

We further examined the expression of COX-2 to determine which cells are the targets of the COX-2 inhibitor etodolac. Some lymphatic endothelial cells (Fig. 3B) and OCUM-2MLN cells (Fig. 3C) expressed COX-2. As shown in Fig. 3C, some F4/80-positive macrophages were also COX-2 positive. These findings suggest that etodolac may act on several different types of cells in this model.

We also investigated the expression levels of mouse mRNA for VEGF-C (Fig. 4D, top) and VEGF-D (Fig. 4D, bottom) in the tumor tissues. Consistent with the results obtained by immunohistochemical analysis, mRNA level for VEGF-C and VEGF-D increased in the orthotopically inoculated tumors. In addition, the expression of VEGF-C, but not that of VEGF-D, was down-regulated after treatment with etodolac.

Effects of etodolac on macrophages, lymphatic endothelial cells, and cancer cells in vitro. Given the coexpression of COX-2 and VEGF-C or VEGF-D in macrophages, we hypothesized that etodolac suppresses the expression of VEGF-C and VEGF-D in macrophages. To test this hypothesis, we examined the mRNA levels of VEGF-C and VEGF-D in in vitro–cultured RAW264.7, a mouse macrophage-like cell line, by quantitative RT-PCR. The levels of expression of COX-2 (Fig. 4A) and VEGF-C (Fig. 4B) were dose-dependently up-regulated at 24 h after stimulation with LPS. The up-regulation of VEGF-C was, however, suppressed by...
treatment with etodolac in a dose-dependent fashion. Ten micro-
molars or higher concentrations of etodolac maximally, although
not completely, suppressed the expression of VEGF-C mRNA
(Fig. 4C). We also examined the expression of VEGF-D, but found
that it was not significantly affected by etodolac (data not shown).

We further examined the effects of etodolac on cells other than
macrophages which are involved in tumor lymphangiogenesis, i.e.,
lymphatic endothelial cells and cancer cells. We used HDLECs to
investigate the effects of etodolac on lymphatic endothelial cells.
The mRNA levels of VEGF-R3 in HDLECs were not affected by
10 μmol/L of etodolac (Fig. 5A). In contrast, cell growth assay
revealed that 3 and 30 μmol/L of etodolac each significantly
suppressed the growth of HDLECs, only upon stimulation with LPS,
although the inhibitory effect of etodolac was not prominent
(Fig. 5B). We also examined the effects of etodolac on the growth
of OCUM-2MLN. However, no significant difference in growth of
OCUM-2MLN cells was observed at 3 days after addition of 3 or
30 μmol/L etodolac (Fig. 5C).

**Suppression of lymphangiogenesis by etodolac in a mouse model of chronic inflammation.** We used a mouse model of
chronic inflammation to determine whether the suppressive effect
of etodolac on tumor lymphangiogenesis holds true for inflamma-
tory lymphangiogenesis. In this model, thioglycollate medium
was given i.p. as a proinflammatory agent to induce chronic
aseptic peritonitis. After repeated i.p. injection (thrice a week for
2 weeks) of thioglycollate medium to immunocompetent BALB/c
mice, inflammatory plaques formed on the peritoneal surface of
the diaphragm (Fig. 6A, top). These plaques were consisted mainly

---

**Figure 4.** Suppression of expression of VEGF-C by etodolac in macrophages in vitro. mRNA levels of COX-2 (A) and
VEGF-C (B) in cultured RAW.264.7, mouse macrophage-like cells, were
determined at 24 h after stimulation with LPS. C, suppression of VEGF-C
expression by treatment with etodolac. Columns, mean; bars, SE.

**Figure 5.** Effects of etodolac on cells other than macrophages. A, mRNA levels of VEGF-R3 (bottom) in HDLECs treated with 10 μmol/L of etodolac with or
without stimulation with 10 ng/mL tumor necrosis factor-α (TNF-α) or 100 ng/mL LPS. Top, up-regulation of COX-2 in HDLECs by stimulation with TNF-α or LPS.
Columns, mean; bars, SE. *n.s., not significant. B, cell growth assay using WST-8 revealed that 3 and 30 μmol/L of etodolac each significantly suppressed the growth of HDLECs upon stimulation with 100 ng/mL LPS; *1, P < 0.001; *2, P < 0.001; *3, P < 0.001; Student’s t test. Columns, mean; bars, SE. C, cell growth
assay with WST-8 revealed that growth of OCUM-2MLN was not affected by etodolac at 3 d after addition of 3 or 30 μmol/L etodolac. Points, mean; bars, SE.
of mononuclear cells (Fig. 6A, bottom). Immunohistochemical analysis revealed that COX-2, VEGF-C, and VEGF-D were highly expressed in these plaques and that many cells positive for VEGF-C and VEGF-D were F4/80-positive macrophages (Fig. 6B).

Using this model, we examined whether etodolac inhibits inflammatory lymphangiogenesis. As shown in Fig. 6C, outgrowths of lymphatic vessels in the plaques were decreased in etodolac-treated mice compared with untreated mice. Quantification of LYVE-1–positive areas in the plaques revealed that induction of lymphangiogenesis was significantly suppressed in etodolac-treated mice compared with control mice (Fig. 6D). These findings indicate that etodolac is able to suppress lymphangiogenesis in tumor tissues, as well as in nontumorous tissue.

Discussion

Many clinical and animal studies have shown that COX-2 induces angiogenesis (34). Meanwhile, there is no direct evidence of a relationship between COX-2 and lymphangiogenesis, although some clinical and animal studies have suggested that level of COX-2 expression in tumor tissue is correlated with lymph node metastasis and/or unfavorable prognosis (24–28, 35). However, none of these studies clearly indicated the status of lymphatic vessels. In the present study, we investigated the effects of COX-2 inhibitor on lymphatic vessels using the lymphatic endothelial cell-specific markers LYVE-1 and Prox1. In the model of lymphatic metastasis, both lymphangiogenesis and angiogenesis were induced around the orthotopic tumors of OCUM-2MLN. We found
that administration of etodolac suppressed tumor lymphangiogenesis along with tumor angiogenesis. In addition, we evaluated the extent of lymph node metastasis and found that the total weight of metastasized lymph node was also decreased by treatment with etodolac. These findings indicated that COX-2 promotes tumor lymphangiogenesis and consequent lymph node metastasis, in addition to tumor angiogenesis as previously reported.

The reproducibility of assignment of highly vascularized areas, i.e., hotspots in tumor tissue sections, is a critical variable in the analysis of lymphangiogenesis (36). Finding relevant hotspots requires training and experience (37). To deal with this potential problem, we established here a new model of tumor lymphangiogenesis in the diaphragm. Since lymphatic vessels in the diaphragm can be immunostained in whole-mount preparations, it is possible to capture the entire network of lymphatics in the diaphragm. There is no need to pick only hotspots for quantification because outgrowth of lymphatic vessels was observed over the entire diaphragm in the model of carcinomatous peritonitis. We quantified the number of sprouts of lymphatic vessels as a marker of lymphangiogenesis, as suggested by Baluk et al. (11). The results using this model confirmed the finding that etodolac suppresses lymphangiogenesis.

Recent studies have shown that inflammatory cells have stimulatory effects on tumor progression (38). In particular, tumor-associated macrophages have been suggested to promote tumor lymphangiogenesis (10, 39). We therefore hypothesized that etodolac suppresses the secretion of lymphangiogenic factors from macrophages. Our finding that some macrophages in tumor stroma expressed COX-2 strongly supports this hypothesis. Furthermore, we found that mRNA levels of VEGF-C was indeed suppressed by etodolac in RAW264.7 cells, as well as in tumor tissues in vivo. Although these findings are not in agreement with a previous report that VEGF-C expression in fibroblasts was not suppressed by indomethacin, a nonselective NSAID (40), this discrepancy may be due to the difference in cell types examined or the COX-2 selectivity of drugs used.

Lymphangiogenesis is also induced in chronic inflammatory lesions (41). Macrophages have recently been shown to be recruited into inflammatory lesions to secrete VEGF-C and induce lymphangiogenesis (11, 12). In the present study, using a model of chronic aseptic peritonitis, we observed that macrophages densely accumulated in inflammatory plaques, wherein lymphangiogenic growth factors are expressed. These findings suggest that COX-2 can enhance lymphangiogenesis in the absence of cancer cells.

We have shown that decrease of lymph node metastasis can be achieved by COX-2 inhibitor, possibly via inhibition of macrophage-mediated lymphangiogenesis. Despite recent studies reporting cardiovascular complications from long-term administration of NSAIDs (42), these drugs may still be applicable to cancer treatment by limiting population and administering periods: NSAIDs should be effective for preventing potential metastases in patients with advanced cancers in presurgical period or in those having inflammation aroused by surgical manipulation in early postsurgical periods. In the latter case, surgery-related inflammation may be accompanied by lymphangiogenesis, which could be a cause of dissemination or metastasis of unexpectedly remained cancer cells.

In conclusion, we believe that our findings may provide a potential usage of COX-2 inhibitors in cancer treatment, which could overcome known obstacles in using these drugs.

Acknowledgments


Grant support: KAKENHI, a grant-in-aid for scientific research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Arisa Mita for expert technical assistance.

References

26. Siironen P, Ristimaki A, Narko K, et al. VEGF-C and
Inhibition of Cyclooxygenase-2 Suppresses Lymph Node Metastasis via Reduction of Lymphangiogenesis

Caname Iwata, Mitsunobu R. Kano, Akiyoshi Komuro, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/67/21/10181

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2007/10/30/67.21.10181.DC1

Cited articles
This article cites 42 articles, 15 of which you can access for free at:
http://cancerres.aacrjournals.org/content/67/21/10181.full.html#ref-list-1

Citing articles
This article has been cited by 19 HighWire-hosted articles. Access the articles at:
/content/67/21/10181.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.